Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuromuscular Blocking Agents Clear all
Completed No phase listed Observational Accepts healthy volunteers

Validation of the REPS Prediction Tool

NCT03585400
View directory record Official record
Conditions
Residual Neuromuscular Blockade, Curarization, Postoperative Residual, Postoperative Respiratory Complication
Interventions
Observational Study
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
101,510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Not applicable Interventional

Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation

NCT04046731
View directory record Official record
Conditions
Allergy
Interventions
Skin Testing
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Jun 10, 2026, 9:20 PM EDT
Completed No phase listed Observational

Severe ARDS: Generating Evidence

NCT03021824
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Acute Respiratory Failure With Hypoxia, Acute Respiratory Failure
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
28
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Jun 10, 2026, 9:20 PM EDT
Completed No phase listed Observational

The Impact of Quantitative Neuromuscular Monitoring in the PACU on Residual Blockade and Postoperative Recovery

NCT01933841
View directory record Official record
Conditions
Muscle Weakness
Interventions
TOF-Watch SX, Notify the provider
Device · Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Jun 10, 2026, 9:20 PM EDT
Completed No phase listed Observational

Incidence of Residual Neuromuscular Blockade in Intra-abdominal Surgery: A Prospective, Observational Study

NCT02984839
View directory record Official record
Conditions
Neuromuscular Blockade, Pulmonary Complication
Interventions
Stimpod NMS450® Nerve Stimulator, by Xavant™ Technology
Device
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jun 10, 2026, 9:20 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase I Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of CW002

NCT01338935
View directory record Official record
Conditions
Healthy
Interventions
CW 002
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 49 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 4 Interventional

Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

NCT05887375
View directory record Official record
Conditions
Spine Surgery, Reversal of Neuromuscular Blockade, Urinary Retention Postoperative
Interventions
Sugammadex, Neostigmine, Glycopyrrolate, Rocuronium
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 4 Interventional Results available

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

NCT03346057
View directory record Official record
Conditions
Reversal of Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex vs Placebo to Prevent Residual Neuromuscular Block

NCT02728726
View directory record Official record
Conditions
General Surgery
Interventions
Sugammadex, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Jacksonville, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Jun 10, 2026, 9:20 PM EDT
Completed No phase listed Observational

Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal

NCT03585348
View directory record Official record
Conditions
Neuromuscular Blockade, Residual Curarisation, Postoperative, Surgery Under General Anaesthesia
Interventions
Neuromuscular blocking agents
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
265,537 participants
Timeline
2018 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

NCT05794503
View directory record Official record
Conditions
Urinary Retention Postoperative, Laparoscopic Cholecystectomy, Neuromuscular Blockade, Sugammadex, Neostigmine, Neuromuscular Blocking Agents, Physiological Effects of Drugs
Interventions
Neostigmine, Sugammadex
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 10, 2026, 9:20 PM EDT
Enrolling by invitation No phase listed Observational

Accuracy and Precision of Train-of-Four Ratios Obtained With Acceleromyography and Electromyography in Restricted-Movement Settings in the Absence of Neuromuscular Blocking Drugs

NCT06805032
View directory record Official record
Conditions
Cystoscopy
Interventions
Observation of EMG and AMG readings
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jun 10, 2026, 9:20 PM EDT
Terminated Phase 4 Interventional Results available

Avoiding Neuromuscular Blockers to Reduce Complications

NCT03962725
View directory record Official record
Conditions
Respiratory Failure, Respiratory Infection, Aspiration Pneumonia, Pneumonitis, Atelectasis, Bronchospasm
Interventions
Neuromuscular Blocking Agents, Anesthetic Adjuncts
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 3 Interventional Results available

Reevaluation Of Systemic Early Neuromuscular Blockade

NCT02509078
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Cisatracurium Besylate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,008 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
44
States / cities
Fresno, California • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 4 Interventional Results available

Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex

NCT03543826
View directory record Official record
Conditions
Muscle Weakness
Interventions
Protocol for rocuronium neuromuscular block
Combination Product
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Not applicable Interventional

Does the Use of a Moisture Chamber Decrease the Incidence of Corneal Abrasions in Critically Ill Pediatric Patients?

NCT00129077
View directory record Official record
Conditions
Eye Injuries, Critically Ill
Interventions
plastic wrap over eye & lubrication applied q6 hrs
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
2 Weeks to 17 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2007 · Synced Jun 10, 2026, 9:20 PM EDT
Completed Phase 4 Interventional

The Early Reversibility of Rocuronium After Different Doses of Neostigmine

NCT00001520
View directory record Official record
Conditions
Paralysis
Interventions
neostigmine
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 9:20 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

NMBA Reversal and Postoperative Urinary Retention

NCT06948409
View directory record Official record
Conditions
Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 10, 2026, 9:20 PM EDT